Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT
Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now.
Puma Biotechnology Inc. (PBYI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,874,713 | $6,430,266 | +3% | 0.01% |
| 2. | D E Shaw D. E. Shaw | 640,780 | $2,197,875 | +13% | 0% |
| 3. | Citadel Investment Group Ken Griffin | 507,818 | $1,741,816 | 0% | |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 451,633 | $1,549,101 | +26% | 0% |
| 5. | Millennium Management Israel Englander | 334,609 | $1,147,709 | -76% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.49 | 28 | $2,309.72 | 30 | 2014-04-11 | Filing | |
| $87.35 | 2 | $174.70 | 2 | 2014-04-09 | Filing | |
| $38.92 | 22,549 | $877,607.08 | 5,686,668 | 2013-11-08 | Filing | |
| $39.60 | 280,700 | $11,115,720.00 | 5,664,119 | 2013-11-05 | Filing | |
| $40.08 | 54,200 | $2,172,336.00 | 5,383,419 | 2013-10-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.37 | 27,000 | $90,909.00 | 41,850 | 2025-07-18 | Filing | |
| $3.54 | 3,935 | $13,910.23 | 204,229 | 2025-07-09 | Filing | |
| $3.53 | 5,587 | $19,738.87 | 208,164 | 2025-07-08 | Filing | |
| $3.54 | 3,443 | $12,171.01 | 164,894 | 2025-07-09 | Filing | |
| $3.53 | 4,374 | $15,453.34 | 168,337 | 2025-07-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,131,299 | $14,170,354 | 9.27% | |
| 2. | 3,835,715 | $13,156,502 | 0% | |
| 3. | 3,706,452 | $12,713,130 | 0% | |
| 4. | 1,342,275 | $4,604,003 | 0% | |
| 5. | 1,150,040 | $3,943,967 | 0% |
News See All
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Latanya, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Sherry, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded.
10 Best Short-Term Stocks To Buy Right Now
Thrilling highs, daunting lows, and the energized chase after the next big opportunity – this thoroughly defines the current stock market.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Darrell and I will be your conference call operator today. At this time, all participants are in a listen-only mode.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Rob, and I'll be your conference call operator today. At this time, all participants are in listen-only mode.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Diego and I will be your conference call operator today. [Operator Instructions] As a reminder, this conference call is being recorded.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.16.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript
Puma Biotechnology, Inc. misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.37. Puma Biotechnology, Inc.
Billionaire Hedge Funds
